Exact Sciences Corp
Open
SectorHealthcare
104.93
Overview
Share price change
24h
Min
104.9
Max
104.96
Income | -66M -86M |
|---|---|
Sales | 28M 878M |
EPS | -0.21 |
Profit margin | -9.786 |
Employees | 7,100 |
EBITDA | -68M -20M |
Recommendations | Neutral |
|---|---|
12 Months Forecast | +0.09% upside |
Market Cap | 404M 20B |
|---|---|
Previous open | 104.93 |
Previous close | 104.93 |
Technical Score
By Trading Central
Confidence
Strong Bullish Evidence
Exact Sciences Corp Chart
Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.
Related News
Peer Comparison
Price change
Exact Sciences Corp Forecast
Price Target
By TipRanks
0.09% upside
12 Months Forecast
Average 105 USD 0.09%
High 105 USD
Low 105 USD
Based on 6 Wall Street analysts offering 12 month price targets forExact Sciences Corp - Dist in the last 3 months.
Financials
$
About Exact Sciences Corp
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services. The company's pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research, and Johns Hopkins University. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.
